Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
190.16
+0.61 (+0.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
47
48
Next >
Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel
June 03, 2024
From
Biogen Inc.
Via
GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
June 01, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
BIIB Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Biogen Inc. Class Action
May 31, 2024
From
Robbins LLP
Via
GlobeNewswire
Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
May 22, 2024
Via
Benzinga
How Is The Market Feeling About Biogen?
May 20, 2024
Via
Benzinga
NASDAQ: BIIB: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Biogen Inc.
May 31, 2024
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
May 31, 2024
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.
Via
Benzinga
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
May 30, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
May 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
May 30, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
May 30, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
May 30, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
May 29, 2024
From
Schall Law
Via
GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
May 28, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Biogen Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Against BIIB
May 28, 2024
From
Robbins LLP
Via
Business Wire
BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
May 28, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm
May 24, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)
May 24, 2024
From
Robbins LLP
Via
GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
May 24, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Biogen Inc. (BIIB) Investors
May 23, 2024
From
Kirby McInerney LLP
Via
Business Wire
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
May 23, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm
May 23, 2024
From
Schall Law
Via
GlobeNewswire
BIIB INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
May 23, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 22, 2024
From
Biogen Inc.
Via
GlobeNewswire
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
May 21, 2024
Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin...
Via
Benzinga
Exposures
Product Safety
Large Cap Biopharmaceuticals Performance
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
May 17, 2024
With new innovation, millions of retiring baby boomers, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead.
Via
InvestorPlace
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
May 16, 2024
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
Via
Benzinga
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024
From
Biogen Inc.
Via
GlobeNewswire
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
May 15, 2024
The company is hoping to launch an under-the-skin version of its infusion, Leqembi.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.